Genetic variation and gene expression in antioxidant related enzymes and risk of COPD: a systematic review
Child and adolescent obesity: part of a bigger picture
NCL Issues a Second Alert to Heed Warnings About Unregulated Versions of GLP-1 Weight Loss Drugs Media Contact: Lisa McDonald, Vice President of Communications, 202-207-2829 Washington, DC A year ago, the National Consumers League took the unusual step of flagging warnings from the Food and Drug Administration (FDA) and medical societies stating that compounded versions of GLP-1 (glucagon-like peptide-1 receptor agonists) weight-loss drugs are not FDA approved and may cause serious health problems
Traditionally, NPs have needed standardized procedures with a supervising physician for clinical services including IV therapy administration and peptide prescribing
On the other hand, a few studies indicate that taking carnitine supplements for six months or longer could actually increase the risk of heart disease
Circulation 150 , 12881298 (2024)